Emergent BioSolutions Reports Fourth Quarter and Twelve Months 2017 Financial Results

Emergent BioSolutions (NYSE:EBS) reported financial results for the quarter and twelve months ended December 31, 2017.

As quoted in the press release:

For Q4 2017, total revenues were $193.8 million, an increase of 28% as compared to 2016. The increase is primarily driven by increased product sales of $74.1 million mainly due to a $63.2 million increase in BioThrax sales as well as sales of products acquired in Q4 2017, partially offset by a $31.6 million reduction in contracts and grants revenue.

Click here to read the full press release.